Document Detail


Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
MedLine Citation:
PMID:  21274875     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: Our findings indicate that the addition of RA to UDCA reduces the bile salt pool size and liver fibrosis and might be an effective supplemental therapy with UDCA for cholestatic diseases.
Authors:
Hongwei He; Albert Mennone; James L Boyer; Shi-Ying Cai
Related Documents :
6275245 - A hypothesis for the mechanism of superoxide production by phagocytic cells.
18206805 - Vascular cytochrome p450 enzymes: physiology and pathophysiology.
8222725 - The platelet-activating factor precursor of the injured cornea is selectively implicate...
3111865 - Mechanisms of arachidonic acid-induced contractions of canine cerebral arteries.
15061595 - Sensitivity of ornithophillic fungi to some drugs.
9053545 - Immunoblot analysis of peroxisomal proteins in liver and fibroblasts from patients.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-12-10
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  53     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-28     Completed Date:  2011-03-18     Revised Date:  2014-09-22    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  548-57     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 American Association for the Study of Liver Diseases.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Bile Acids and Salts / metabolism
Bile Ducts / surgery
Cell Proliferation
Cells, Cultured
Cholestasis, Intrahepatic / metabolism,  pathology*,  prevention & control*
Cholesterol 7-alpha-Hydroxylase / metabolism
Collagen Type I / metabolism
Disease Models, Animal
Hepatocytes / drug effects*,  metabolism,  pathology*
Humans
Ligation
Liver / drug effects,  metabolism,  pathology
Male
Matrix Metalloproteinase 2 / metabolism
Rats
Rats, Sprague-Dawley
Smad2 Protein / metabolism
Tretinoin / pharmacology,  therapeutic use*
Ursodeoxycholic Acid / pharmacology,  therapeutic use*
Grant Support
ID/Acronym/Agency:
DK25636/DK/NIDDK NIH HHS; DK34989/DK/NIDDK NIH HHS; P30 DK034989/DK/NIDDK NIH HHS; P30 DK034989-277466/DK/NIDDK NIH HHS; R37 DK025636/DK/NIDDK NIH HHS; R37 DK025636-33/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Bile Acids and Salts; 0/Collagen Type I; 0/Smad2 Protein; 0/collagen type I, alpha 1 chain; 5688UTC01R/Tretinoin; 724L30Y2QR/Ursodeoxycholic Acid; EC 1.14.13.17/CYP7A1 protein, human; EC 1.14.13.17/CYP7A1 protein, rat; EC 1.14.13.17/Cholesterol 7-alpha-Hydroxylase; EC 3.4.24.24/Matrix Metalloproteinase 2
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in typ...
Next Document:  Different biochemical correlates for different neuropsychiatric abnormalities in patients with cirrh...